{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:02:47Z","timestamp":1746417767939,"version":"3.40.4"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Wuhan Science and Technology bureau project","award":["W2020265"],"award-info":[{"award-number":["W2020265"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In the current literature, it is still controversial whether intravitreal aflibercept injection can provide better vision restoration compared with vitrectomy with panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) patients. Given that there is no high-quality meta-analysis or review to incorporate existing evidence, the purpose of this study is to systematically review the level I evidence in the literature to ascertain whether intravitreal aflibercept injection can provide better vision restoration compared with vitrectomy with PRP for PDR patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The systematic literature review is structured to adhere to PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses), which include requirements deemed essential for the transparent reporting of results. A systematic search will be performed in Web of Science, Embase, Scopus, Science Direct, Cochrane Library up to and inclusive of March 19, 2021. The method of data extraction will follow the approach outlined by the Cochrane Handbook for Systematic Reviews of Interventions. The primary outcome is change in best-corrected visual acuity. The secondary outcomes are change in area of neovascularization and change in area of retinal nonperfusion. Where disagreement occurs, this will be resolved through discussion. All outcomes are pooled on random-effect model. A <jats:italic toggle=\"yes\">P<\/jats:italic> value of &lt;\u200a.05 is considered to be statistically significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The results of our review will be reported strictly following the PRISMA criteria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The hypothesis of the study was that visual acuity recovery would be faster with vitrectomy because the blood is mechanically cleared during surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration number:<\/jats:title>\n            <jats:p>10.17605\/OSF.IO\/NCAXW.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025354","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T04:50:10Z","timestamp":1617857410000},"page":"e25354","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Clinical efficacy of intravitreal aflibercept injection versus vitrectomy with panretinal photocoagulation for patients with proliferative diabetic retinopathy"],"prefix":"10.1097","volume":"100","author":[{"given":"Yao","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxia","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1773-8813","authenticated-orcid":false,"given":"Yi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"212532","DOI":"10.7573\/dic.212532","article-title":"The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy","volume":"7","author":"Zhao","year":"2018","journal-title":"Drugs Context"},{"key":"R2-20250504","article-title":"Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis","author":"Fallico","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ophtha.2003.05.008","article-title":"Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision","volume":"110","author":"Shimura","year":"2003","journal-title":"Ophthalmology"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2337\/diabetes.54.4.1141","article-title":"Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor","volume":"54","author":"Lebherz","year":"2005","journal-title":"Diabetes"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1097\/IAE.0000000000000723","article-title":"Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: a systematic review and meta-analysis","volume":"35","author":"Simunovic","year":"2015","journal-title":"Retina"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"R9-20250504","first-page":"357","article-title":"Genetically engineered fusion proteins for treatment of cancer","volume":"9","author":"Weidle","year":"2012","journal-title":"Cancer Genomics Proteomics"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"e008405","DOI":"10.1136\/bmjopen-2015-008405","article-title":"Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial","volume":"5","author":"Sivaprasad","year":"2015","journal-title":"BMJ Open"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52\u200aweeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1167\/iovs.17-23509","article-title":"Mechanistic evaluation of panretinal photocoagulation versus aflibercept in proliferative diabetic retinopathy: CLARITY substudy","volume":"59","author":"Nicholson","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1001\/jama.2020.23027","article-title":"Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic Retinopathy: a randomized clinical trial","volume":"324","author":"Antoszyk","year":"2020","journal-title":"JAMA"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:19:25Z","timestamp":1746339565000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025354"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":13,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025354","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"2021-03-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}